- Home
- BLFS vs AVXL Comparison
BLFS vs AVXL Comparison
Compare BLFS & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- AVXL
- Stock Information
- Founded
- BLFS 1987
- AVXL 2004
- Country
- BLFS United States
- AVXL United States
- Employees
- BLFS N/A
- AVXL N/A
- Industry
- BLFS Medical/Dental Instruments
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLFS Health Care
- AVXL Health Care
- Exchange
- BLFS Nasdaq
- AVXL Nasdaq
- Market Cap
- BLFS 1.2B
- AVXL 956.7M
- IPO Year
- BLFS 1989
- AVXL N/A
- Fundamental
- Price
- BLFS $26.31
- AVXL $9.80
- Analyst Decision
- BLFS Strong Buy
- AVXL Strong Buy
- Analyst Count
- BLFS 7
- AVXL 2
- Target Price
- BLFS $30.86
- AVXL $44.00
- AVG Volume (30 Days)
- BLFS 356.3K
- AVXL 1.2M
- Earning Date
- BLFS 11-11-2025
- AVXL 08-12-2025
- Dividend Yield
- BLFS N/A
- AVXL N/A
- EPS Growth
- BLFS N/A
- AVXL N/A
- EPS
- BLFS N/A
- AVXL N/A
- Revenue
- BLFS $93,468,000.00
- AVXL N/A
- Revenue This Year
- BLFS $26.07
- AVXL N/A
- Revenue Next Year
- BLFS $16.86
- AVXL N/A
- P/E Ratio
- BLFS N/A
- AVXL N/A
- Revenue Growth
- BLFS 68.16
- AVXL N/A
- 52 Week Low
- BLFS $19.10
- AVXL $5.03
- 52 Week High
- BLFS $29.55
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- BLFS 57.56
- AVXL 58.71
- Support Level
- BLFS $24.33
- AVXL $8.80
- Resistance Level
- BLFS $27.42
- AVXL $10.04
- Average True Range (ATR)
- BLFS 0.89
- AVXL 0.49
- MACD
- BLFS 0.08
- AVXL 0.18
- Stochastic Oscillator
- BLFS 70.51
- AVXL 73.79
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.